Dr. Kunal N. Bhatt, MD
Heart Failure & Transplant Cardiology (Advanced Heart Failure and Transplant Cardiology Physician)
- Medicare participating
At a glance
- Medical school
- Rutgers R W Johnson Medical School (Cam/New Bruns/Pisc) (2008)
- Years since graduation
- 18
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 463
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Medical school: Rutgers R W Johnson Medical School (Cam/New Bruns/Pisc)
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Advanced Heart Failure and Transplant Cardiology Physician primary
GA license 066256 -
Cardiovascular Disease Physician
GA license 066256 -
Internal Medicine Physician
GA license 066256
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Map: Heart Failure & Transplant Cardiology per capita by county →
Where they work
Hospitals
- Emory University Hospital Atlanta, GA
- Emory University Hospital Midtown Atlanta, GA
Medical groups
- The Emory Clinic Inc (3,568 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 463
- Services billed
- 956
- Patients’ average age
- 69
| Service | Times | Patients |
|---|---|---|
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 342 | 337 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 204 | 65 |
| Established patient office or other outpatient visit, 30-39 minutes | 161 | 118 |
| Established patient office or other outpatient visit, 40-54 minutes | 68 | 57 |
| Evaluation of lower heart chamber assist device | 43 | 16 |
| Heart muscle strain imaging | 33 | 33 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 33 | 32 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 23 | 20 |
| Hospital discharge day management, more than 30 minutes | 23 | 22 |
| New patient office or other outpatient visit, 60-74 minutes | 21 | 21 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Vyndamax (tafamidis) | 755 |
| Torsemide Other prescribers in Atlanta, GA | 192 |
| Entresto (sacubitril/valsartan) Other prescribers in Atlanta, GA | 174 |
| Spironolactone Other prescribers in Atlanta, GA | 171 |
| Pantoprazole Sodium Other prescribers in Atlanta, GA | 150 |
| Farxiga (dapagliflozin propanediol) Other prescribers in Atlanta, GA | 145 |
| Pravastatin Sodium Other prescribers in Atlanta, GA | 127 |
| Eliquis (apixaban) Other prescribers in Atlanta, GA | 125 |
| Amlodipine Besylate Other prescribers in Atlanta, GA | 121 |
| Metoprolol Succinate Other prescribers in Atlanta, GA | 119 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $213,940 in research payments for these studies, mostly to the institutions running them.
- A phase 3,radomized,double-blind,placebo-controlled,multicenter study to evaluate the efficacy and safety of amyloid depleter ALXN2220 in adult participants wiith transthyretin amyloid cardiomyopathy ATTR CM
Alexion Pharmaceuticals, Inc. - Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
Eidos Therapeutics, Inc. · Recruiting · NCT06563895 - An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
Ionis Pharmaceuticals, Inc. · Enrolling by invitation · NCT05667493 - CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
Ionis Pharmaceuticals, Inc. · Completed · NCT04136171
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.